Trial Profile
An Open-label, Randomized Two-Part, Two-Period Crossover Study to Demonstrate the Definitive Bioequivalence After Administration of Final Market Image (FMI) Sitagliptin /Metformin 50/500 mg and 50/1000 mg Fixed Dose Combination (FDC) and Concomitant Administration of 50 mg Doses of Sitagliptin and 500 or 1000 mg Doses of Metformin as Individual Tablets
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 11 May 2022
Price :
$35
*
At a glance
- Drugs Metformin/sitagliptin (Primary) ; Metformin; Sitagliptin
- Indications Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Merck & Co; Merck Sharp & Dohme Corp.
- 29 Aug 2009 New trial record